No significantly increased risk seen with exposure to different triptan intensities and duration, alone or in combination with other preventive medications<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
WEDNESDAY, May 21, 2025 (HealthDay News) — Children prenatally exposed to different triptan intensities and duration, alone or in combination with other preventive medications for migraine, do not have increased risk of neurodevelopmental outcomes, according to a study published online May 21 in Neurology<\/em>.<\/p>\n Margherita Camanni, from the University of Milano-Bicocca in Italy, and colleagues examined the effect of different intensities and durations of prenatal exposure to triptans on neurodevelopmental disorders (NDDs) in children in a nationwide health registry study including pregnancies of women with migraine before pregnancy.<\/p>\n Data were included for 26,210 pregnancies of women with migraine: 4,929 were nonmedicated and 21,281 were medicated with triptans in the year of prepregnancy. The researchers identified four group-based trajectories of triptans alone and combined with preventive medications: discontinuers before (low use), early discontinuers (short-term low use), late discontinuers (moderate use), and late discontinuers (high use). During follow-up (mean, eight years), 4.3 percent of the children had a NDD. Compared with children of nonmedicated women, children born to women with any triptan trajectory had a slightly higher risk of NDD (magnitude range of the weighted hazard ratio, 1.05 to 1.16). When discontinuers before (low use) acted as a comparator or when analyzing speech\/language disorders or attention-deficit\/hyperactivity disorder, these risks decreased to null. The risk of autism disorders was slightly, but not significantly, elevated with both triptan late discontinuation trajectories.<\/p>\n “Our results contribute to the limited existing literature and aid pregnant women with migraine and their health care providers in making evidence-based decisions about pharmacologic treatment with triptans and other migraine medications during gestation,” the authors write.<\/p>\n Abstract\/Full Text (subscription or payment may be required<\/a><\/p>\n